BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 36695469)

  • 1. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
    Merad Y; Gaymard A; Cotte L; Perpoint T; Alfaiate D; Godinot M; Becker A; Cannesson O; Batalla AS; Oria-Yassir F; Landré S; Morfin F; Bouscambert M; Valour F; Ader F; Conrad A
    Euro Surveill; 2022 Dec; 27(50):. PubMed ID: 36695469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study.
    Fontán-Vela M; Hernando V; Olmedo C; Coma E; Martínez M; Moreno-Perez D; Lorusso N; Vázquez Torres M; Barbas Del Buey JF; Roig-Sena J; Pastor E; Galmés Truyols A; Artigues Serra F; Sancho Martínez RM; Latasa Zamalloa P; Pérez Martínez O; Vázquez Estepa A; García Rojas AJ; Barreno Estévez AI; Sánchez-Migallón Naranjo A; Pérez Martín JJ; Peces Jiménez P; Morales Romero R; Castilla J; García Cenoz M; Huerta Huerta M; Boone ALD; Macías Ortiz MJ; Álvarez Río V; Rodríguez Recio MJ; Merino Díaz M; Berradre Sáenz B; Villegas-Moreno MT; Limia A; Diaz A; Monge S;
    Clin Infect Dis; 2024 Feb; 78(2):476-483. PubMed ID: 37864849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of mpox infection in individuals who received a first dose of modified vaccinia Ankara immunisation.
    Agunbiade S; Burton F; Muirhead J; Whitlock GG; Girometti N
    Sex Transm Infect; 2023 May; 99(3):198-199. PubMed ID: 36596674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
    Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
    Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of a single dose of mpox vaccine in males.
    Wolff Sagy Y; Zucker R; Hammerman A; Markovits H; Arieh NG; Abu Ahmad W; Battat E; Ramot N; Carmeli G; Mark-Amir A; Wagner-Kolasko G; Duskin-Bitan H; Yaron S; Peretz A; Arbel R; Lavie G; Netzer D
    Nat Med; 2023 Mar; 29(3):748-752. PubMed ID: 36720271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox.
    Deng L; Lopez LK; Glover C; Cashman P; Reynolds R; Macartney K; Wood N
    JAMA; 2023 Jun; 329(23):2091-2094. PubMed ID: 37145654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines.
    Cornelisse VJ; Kearley JJM; Vargas Castillo J; Macharg L; McLaughlin VA; Jack SJ; Swift C
    Sex Health; 2023 Dec; 20(6):585-587. PubMed ID: 37852607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
    Muller MP; Navarro C; Wilson SE; Shulha HP; Naus M; Lim G; Padhi S; McGeer A; Finkelstein M; Liddy A; Bettinger JA;
    Vaccine; 2024 Jan; 42(3):535-540. PubMed ID: 38199921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing the acute antibody response of monkeypox and MVA-BN vaccine following an Australian outbreak.
    Asquith W; Hueston L; Dwyer D; Kok J; Ko D; Fennel M; Rockett R; Rai NJ; Li Y; Sriramoju S; Sutor A; O'Sullivan M
    J Med Virol; 2024 Jan; 96(1):e29407. PubMed ID: 38240403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine protect against mpox?
    Ogoina D; Strub-Wourgaft N
    Lancet Infect Dis; 2023 Jul; 23(7):768-769. PubMed ID: 36924788
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting vaccine effectiveness for mpox.
    Berry MT; Khan SR; Schlub TE; Notaras A; Kunasekaran M; Grulich AE; MacIntyre CR; Davenport MP; Khoury DS
    Nat Commun; 2024 May; 15(1):3856. PubMed ID: 38719852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified vaccinia Ankara-Bavarian Nordic vaccine against mpox in children.
    Turtle L; Subramaniam K
    Lancet Infect Dis; 2023 Sep; 23(9):989-990. PubMed ID: 37336223
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
    Payne AB; Ray LC; Cole MM; Canning M; Houck K; Shah HJ; Farrar JL; Lewis NM; Fothergill A; White EB; Feldstein LR; Roper LE; Lee F; Kriss JL; Sims E; Spicknall IH; Nakazawa Y; Gundlapalli AV; Shimabukuro T; Cohen AL; Honein MA; Mermin J; Payne DC
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(49):1560-1564. PubMed ID: 36480479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023.
    Dalton AF; Diallo AO; Chard AN; Moulia DL; Deputy NP; Fothergill A; Kracalik I; Wegner CW; Markus TM; Pathela P; Still WL; Hawkins S; Mangla AT; Ravi N; Licherdell E; Britton A; Lynfield R; Sutton M; Hansen AP; Betancourt GS; Rowlands JV; Chai SJ; Fisher R; Danza P; Farley M; Zipprich J; Prahl G; Wendel KA; Niccolai L; Castilho JL; Payne DC; Cohn AC; Feldstein LR; ;
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):553-558. PubMed ID: 37200229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic and Subclinical Mpox: An Association With Modified Vaccinia Ankara Vaccine.
    Golden MR; Soge OO; Mills M; Berzkalns A; Cannon C; Ramchandani M; Dombrowski JC; Karmarkar EN; Chow EJ; Gov JP; Swenson P; Greninger AL
    Sex Transm Dis; 2024 May; 51(5):342-347. PubMed ID: 38301634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox - United States, May 22, 2022-January 31, 2023.
    Owens LE; Currie DW; Kramarow EA; Siddique S; Swanson M; Carter RJ; Kriss JL; Boersma PM; Lee FC; Spicknall I; Hurley E; Zlotorzynska M; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(13):342-347. PubMed ID: 36995962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons - 29 U.S. Jurisdictions, May 22-September 3, 2022.
    Farrar JL; Lewis NM; Houck K; Canning M; Fothergill A; Payne AB; Cohen AL; Vance J; Brassil B; Youngkin E; Glenn B; Mangla A; Kupferman N; Saunders K; Meza C; Nims D; Soliva S; Blouse B; Henderson T; Banerjee E; White B; Birn R; Stadelman AM; Abrego M; McLafferty M; Eberhart MG; Pietrowski M; De León SM; Creegan E; Diedhiou A; Wiedeman C; Murray-Thompson J; McCarty E; Marcinkevage J; Kocharian A; Torrone EA; Ray LC; Payne DC;
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1610-1615. PubMed ID: 36580416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022.
    Rosenberg ES; Dorabawila V; Hart-Malloy R; Anderson BJ; Miranda W; O'Donnell T; Gonzalez CJ; Abrego M; DelBarba C; Tice CJ; McGarry C; Mitchell EC; Boulais M; Backenson B; Kharfen M; McDonald J; Bauer UE
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):559-563. PubMed ID: 37339074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serosurvey of Immunity to Monkeypox (Mpox) Virus Antigens in People Living with HIV in South Florida.
    Kupritz J; Pahwa S; Pallikkuth S
    Pathogens; 2023 Nov; 12(11):. PubMed ID: 38003819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.